{"id":813044,"date":"2026-05-21T21:06:16","date_gmt":"2026-05-21T21:06:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/813044\/"},"modified":"2026-05-21T21:06:16","modified_gmt":"2026-05-21T21:06:16","slug":"canadians-can-now-get-digital-prescriptions-for-generic-ozempic","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/813044\/","title":{"rendered":"Canadians can now get digital prescriptions for ‘generic Ozempic’"},"content":{"rendered":"\n

Telehealth provider Hims & Hers Health Inc.<\/a> announced Thursday the availability of generic semaglutide through its platform, allowing eligible Canadians access to digital prescriptions for the popular drug widely used for weight loss.<\/p>\n

With Health Canada\u2019s approval of the first two generic injection semaglutide, the medication popularized by the brand name Ozempic, Canadians can now access a more affordable version of the drug prescribed in the treatment of type 2 diabetes but widely used off-label as an anti-obesity medication.<\/p>\n

Hims & Hers has started offering eligible customers personalized treatment plans starting at $149\/month, which would include the medication.<\/p>\n

\u201cGeneric medication will be more affordable than other options, and I think that will be a particularly attractive opportunity for Canadians,\u201d Austin Kouri, general manager of Hims & Hers Canada, said in an interview. \u201cThis is obviously a little bit of an unprecedented environment, with Canada being one of the first to bring generics in the market.\u201d<\/p>\n

Canada is the first in the G7 to have an approved generic version of semaglutide, following Health Canada<\/a>\u2018s approval of one made by Indian pharmaceutical company Dr. Reddy\u2019s Laboratories on April 28 and a second one from Canadian pharmaceutical giant Apotex Inc. on May 1.<\/p>\n

Hims & Hers will be offering Apotex\u2019s Apo-semaglutide injection, the generic equivalent of Ozempic launched earlier this month.<\/p>\n

Apotex\u00a0said the product is shipping this week to wholesalers and distributors\u00a0nationally and should be available to Canadians at their local pharmacies by the end of this week or early next.\u00a0<\/p>\n

\u201cThe launch of Apo-semaglutide injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada,\u201d Martin Ar\u00e8s, president of\u00a0Apotex\u00a0Canada, said in a press release when the generic drug launched.\u00a0<\/p>\n

Health Canada is also reviewing seven other submissions for generic semaglutides by different companies, it said. These include Ozempic-maker Novo Nordisk\u2019s second brands\u00a0Plosbrio\u00a0(similar to\u00a0Ozempic) and\u00a0Poviztra\u00a0(similar to\u00a0Wegovy), which the Danish pharmaceutical company said were filed to \u201cmaintain flexibility,\u201d although it has\u00a0yet to make\u00a0any decisions\u00a0around\u00a0launching\u00a0the products.\u00a0<\/p>\n

Earlier this year, Novo Nordisk lost its Canadian patent protection on its popular semaglutide-based drugs, Ozempic and\u00a0Wegovy, after\u00a0apparently failing\u00a0to pay a small fee to\u00a0maintain\u00a0the patent.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Telehealth provider Hims & Hers Health Inc. announced Thursday the availability of generic semaglutide through its platform, allowing…\n","protected":false},"author":3,"featured_media":813045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[2147,330267,205624,210,92091,1060,9412,15209,67,132,68],"class_list":["post-813044","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-canada","tag-generic-equivalent","tag-generic-version","tag-health","tag-health-canada","tag-medication","tag-novo-nordisk","tag-semaglutide","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116614606899478036","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/813044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=813044"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/813044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/813045"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=813044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=813044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=813044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}